uniQure Announces New Preclinical Data in Hemophilia A and Fabry Disease in Oral Presentations at the 22nd ASGCT Annual Meeting
May 02, 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 02, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
Abeona Therapeutics to Report New Preclinical Data Demonstrating Therapeutic Potential of ABO-401 for Treatment of Cystic Fibrosis at American Society of Gene and Cell Therapy Annual Meeting
April 30, 2019 08:00 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, April 30, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today will report new preclinical data...
Abeona Therapeutics to Present Data for ABO-401 in Cystic Fibrosis and Retinal Disorders at the American Society of Gene and Cell Therapy Annual Meeting
April 15, 2019 14:41 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, April 15, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that new data demonstrating...
uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
April 15, 2019 12:15 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 15, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 Neutralizing Antibodies
May 21, 2018 07:00 ET
|
uniQure Inc.
-- New Data Further Demonstrating Favorable Immunogenicity Profile of AAV5 -- -- Data Suggest AAV5 Gene Therapies May be Viable Treatments for at Least 97% of Patients -- -- Data Presented at the...
Abeona Therapeutics Provides Clinical Update on MPS IIIA Gene Therapy Trial at the 21st Annual ASGCT Meeting
May 18, 2018 09:25 ET
|
Abeona Therapeutics Inc.
ABO-102 18-month efficacy and safety data continue to demonstrate time- and dose-dependent reductions in underlying disease pathology, including decreased CSF and urine GAGs and improved liver...
uniQure Presents Preclinical Data Demonstrating Advances in the Distribution of Gene Therapy
May 18, 2018 07:00 ET
|
uniQure Inc.
-- Preclinical Data Presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Chicago -- LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 18, 2018 (GLOBE NEWSWIRE)...
Voyager Therapeutics Announces New Data at the American Society of Gene and Cell Therapy 2018 Annual Meeting
May 17, 2018 18:15 ET
|
Voyager Therapeutics, Inc.
VY-SOD101 achieves meaningful suppression of disease-causing gene of ALS in large mammals after a one-time administration Results during the second half of 2018 from further delivery optimization...
Abeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT Meeting
May 17, 2018 09:20 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 17, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Announces Upcoming Presentations
May 08, 2018 08:15 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 08, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical- stage biopharmaceutical company focused on developing novel cell and gene...